Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity

Area of Science:

• Pharmacology
• Oncology
• Toxicology

Background:

• Cisplatin is a widely used chemotherapy drug.
• Cisplatin can cause significant kidney damage (nephrotoxicity).
• Strategies to mitigate cisplatin nephrotoxicity are crucial for patient care.

Purpose of the Study:

• To investigate the effect of cimetidine on cisplatin-induced nephrotoxicity.
• To determine if cimetidine influences the antitumor efficacy of cisplatin.
• To explore the mechanisms underlying cimetidine's protective effects.

Main Methods:

• In vitro and in vivo experiments were conducted.
• Cell viability assays were performed on kidney and osteosarcoma cells.
• Reactive oxygen species (ROS) production was measured.
• Platinum concentration in cells was analyzed.
• Cimetidine was administered via intravenous infusion.

Main Results:

• Cimetidine administration prevented cisplatin-induced nephrotoxicity in vivo.
• Cimetidine did not compromise the antitumor activity of cisplatin against osteosarcoma cells.
• Cimetidine and N-acetylcysteine (NAC) inhibited cisplatin's growth inhibition in kidney cells but not osteosarcoma cells.
• Cimetidine and NAC reduced cisplatin-induced ROS production in kidney cells.
• Cimetidine did not affect platinum uptake in cells via OCT2.

Conclusions:

• Cimetidine effectively reduces cisplatin-induced nephrotoxicity.
• Cimetidine preserves the antitumor effects of cisplatin on osteosarcoma.
• The protective mechanism involves the reduction of ROS in kidney cells.